


COVID-19 (SARS-CoV-2) IgM and IgG ELISA

COVID-19 specific IgM and IgG antibody detection is an ideal complement to early Corona Virus detection!

COVID-19 (Corona Virus Disease) is caused by **2019-nCoV (SARS-CoV-2)** which is mainly transmitted through respiratory droplets. Symptoms of COVID-19 may appear 1-14 days after exposure and mainly include: fever, cough and shortness of breath.



Currently, RT-PCR tests are being used to diagnose the patients worldwide because of its availability. However, RT-PCR based diagnosis has its limitation. Detecting SARS-CoV-2 by RT-PCR requires high-quality nasopharyngeal specimens that contain an enough amount of intact viral RNA. The challenges associated with collection of this specimen type has led to many reported high false-negative rates

The advantage of immunoassays is their ability to detect recent and past infections. IgG antibodies are long-lasting and can persist in the bloodstream for many years after infection. This test has the advantage of detecting not only individuals with active infection, but also those who were previously exposed to the virus and have subsequently developed immunity.

COVID-19 (SARS-CoV-2) IgM ELISA ID E-1100 IgM		96 WELLS
<i>ELISA for the specific and semi-quantitative detection of human IgM antibodies against Coronavirus SARS-CoV-2 (COVID-19) in human serum and plasma.</i>		
<i>IgM antibodies are the first immunoglobulin to be produced in response to an antigen and are primarily present during the early stage of the disease. They can serve as evidence of infection with Coronavirus infectious disease.</i>		
Principle:	ELISA, semi-quantitative	Advantages: <ul style="list-style-type: none"> CE-marked; for IVD Specific and sensitive detection of antibodies against SARS-CoV-2 virus Assay designed with “IgM capture” method Results within 1.5 hours Samples can be stored – no need to run the same day of blood withdrawal Semi-quantitative
Sample Type:	Human serum and plasma	
Sample Volume:	10 µL	
Assay Incubation:	45 / 45 / 8-12 min	
Performance:		
Sensitivity	100%	
Specificity	98.5%	

COVID-19 (SARS-CoV-2) IgG ELISA ID E-1000 IgG		96 WELLS
<i>ELISA for the specific and semi-quantitative detection of human IgG antibodies against Coronavirus SARS-CoV-2 (COVID-19) in human serum and plasma.</i>		
<i>IgG antibodies are the most abundantly found immunoglobulin to be produced in response to an antigen and will be maintained in the body after initial exposure for long term response.</i>		
Principle:	ELISA, semi-quantitative	Advantages: <ul style="list-style-type: none"> CE-marked; for IVD Specific and sensitive detection of antibodies against SARS-CoV-2 virus Results within 1.5 hours Samples can be stored – no need to run the same day of blood withdrawal Semi-quantitative determination for serum and plasma
Sample Type:	Human serum and plasma	
Sample Volume:	10 µL	
Assay Incubation:	45 / 45 / 8-12 min	
Performance:		
Sensitivity	95%	
Specificity	98,3%	

WORLD-WIDE LDN Labor Diagnostika Nord GmbH & Co. KG

Am Eichenhain 1 - 48531 Nordhorn, Germany - Tel.: +49 5921 8197-101 - Fax: +49 5921 8197-222 - www.ldn.de - info@ldn.de

NORTH AMERICA Rocky Mountain Diagnostics Inc.

703 N Tejon Suite C - Colorado Springs - CO 80903 - Tel: 1-877-477-0039 - Fax: 1-719-477-0307 - www.rmdiagnosics.com - info@rmdiagnosics.com